HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Weight loss supplements are a big industry, but do they actually work? A dietitian explores the evidence, efficacy, and safety of common weight loss supplements.

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

A study by Mass General Brigham found that taking the weight-loss drug semaglutide before bariatric surgery does not lead to better overall weight loss outcomes. The research suggests that ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

Customers can expect a rate hike up to 14 percent as employee welfare costs surge related to Ozempic and drugs like it.